TDP 43 News and Research

RSS

Study shows improved detection of dementia paves the way for refined clinical trials testing

A series of studies demonstrate improved detection of the second most common form of dementia, providing diagnostic specificity that clears the way for refined clinical trials testing targeted treatments.

18 Mar 2013

‘New Frontiers in Neurodegenerative Disease Research’ symposium to be held from Feb. 4-7

At the Keystone Symposium "New Frontiers in Neurodegenerative Disease Research," held 4-7 February in Santa Fe, New Mexico, researchers explored the processes that lead to a variety of diseases, including Alzheimer's and Lou Gehrig's disease (amyotrophic lateral sclerosis, ALS).

7 Mar 2013

Researchers discover new candidate disease proteins for neurodegenerative disorders

A multi-institution group of researchers has found new candidate disease proteins for neurodegenerative disorders.

4 Mar 2013

Study identifies how new ALS gene mutations cause other diseases of the brain, muscle and bone

Researchers supported by The ALS Association have discovered how mutations in new amyotrophic lateral sclerosis (ALS) genes cause not only ALS but also other diseases of the brain, muscle and bone.

4 Mar 2013

Shortage of TDP-43 protein causes muscle wasting and stunted nerve cells

A shortage of a protein called TDP-43 caused muscle wasting and stunted nerve cells. This finding supports the idea that malfunction of this protein plays a decisive role in ALS and FTD. The study is published in the "Proceedings of the National Academy of Sciences of the USA" (PNAS).

3 Mar 2013

Abnormal TDP-43 protein causes death of astrocytes in motor neurone disease

A discovery using stem cells from a patient with motor neurone disease could help research into treatments for the condition. The study used a patient's skin cells to create motor neurons - nerve cells that control muscle activity - and the cells that support them called astrocytes.

13 Feb 2013

Scientists uncover TDP-43 protein as possible target for treatment of ALS, FTD

Neuroscientists at Georgetown University Medical Center say they have new evidence that challenges scientific dogma involving two fatal neurodegenerative diseases - amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD) - and, in the process, have uncovered a possible therapeutic target as a novel strategy to treat both disorders.

20 Dec 2012

Dementia therapy: an interview with Assoc Prof. Olivier Piguet and Sharon Savage

Dementia is the umbrella term used to describe a number of neurodegenerative brain disorders that cause progressive changes in thinking abilities and behaviour. The kind of deficits experienced by individuals diagnosed with dementia depends on the location and severity of the pathology in the brain.

11 Dec 2012

Lack of TDP-43 protein can lead to frontotemporal dementia/ALS

Researchers at Mayo Clinic in Florida have uncovered a toxic cellular process by which a protein that maintains the health of neurons becomes deficient and can lead to dementia.

11 Dec 2012

New way to protect neurons that express mutant huntingtin proteins

By using a model, researchers at the University of Montreal have identified and "switched off" a chemical chain that causes neurodegenerative diseases such as Huntington's disease, amyotrophic lateral sclerosis and dementia. The findings could one day be of particular therapeutic benefit to Huntington's disease patients. "We've identified a new way to protect neurons that express mutant huntingtin proteins," explained Dr. Alex Parker of the University of Montreal's Department of Pathology and Cell Biology and its affiliated CRCHUM Research Centre.

27 Nov 2012

Researchers use baker's yeast to identify new therapies for Lou Gehrig's disease

Amyotrophic lateral sclerosis, also called Lou Gehrig's disease, is a devastatingly cruel neurodegenerative disorder that robs sufferers of the ability to move, speak and, finally, breathe.

29 Oct 2012

Study describes how Dbr1 gene halts toxic buildup of TDP-43-a protein

Scientists at the Gladstone Institutes and the Stanford University School of Medicine have discovered how modifying a gene halts the toxic buildup of a protein found in nerve cells. These findings point to a potential new tactic for treating a variety of neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease)-a fatal disease for which there is no cure.

29 Oct 2012

Common RNA pathway links frontotemporal lobar dementia with ALS

Two proteins previously found to contribute to ALS, also known as Lou Gehrig's disease, have divergent roles. But a new study, led by researchers at the Department of Cellular and Molecular Medicine at the University of California, San Diego School of Medicine, shows that a common pathway links them.

1 Oct 2012

Rapamycin can alleviate frontotemporal lobar degeneration

A southern Taiwan-based National Cheng Kung University (NCKU) research team has discovered that rapamycin, a drug as a autophagy activator is a possible treatment to alleviating frontotemporal lobar degeneration (FTLD), one of the mainly causes of dementia, and so far no medication can be used.

29 Sep 2012

TauRx initiates LMTX Phase 3 trial in Pick's Disease

TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held 5-7 September in Manchester, England, underscores the need for new treatments for this form of dementia that is similar to Alzheimer's Disease, except that it tends to damage different areas of the brain and affects people as early as 40 years old.

10 Sep 2012

Anacardic acid can rescue some ALS phenotypes in vitro

A research group at the Center for iPS Cell Research and Application (CiRA) at Japan's Kyoto University has successfully recapitulated amyotrophic lateral sclerosis (ALS)-associated abnormalities in motor neurons differentiated from induced pluripotent stem cells (iPSCs) obtained from patients with familial ALS, a late-onset, fatal disorder which is also known for Lou Gehrig's disease. In a drug screening assay using the disease model, the team further found that the chemical compound anacardic acid can rescue some ALS phenotypes in vitro.

3 Aug 2012

Researchers link newly discovered gene mutations to ALS

Researchers have linked newly discovered gene mutations to some cases of the progressive fatal neurological disease amyotrophic lateral sclerosis - ALS, also known as Lou Gehrig's disease. Shedding light on how ALS destroys the cells and leads to paralysis, the researchers found that mutations in this gene affect the structure and growth of nerve cells.

16 Jul 2012

Cedars-Sinai scientist receives ALS Association Golden West Chapter Commitment to a Cure Award

Robert H. Baloh, MD, PhD, director of Cedars-Sinai Medical Center's Neuromuscular Division, has received the ALS Association Golden West Chapter Commitment to a Cure Award.

30 Apr 2012

Researchers use skin cells from MND patient to create motor neurones

A breakthrough using cutting-edge stem cell research could speed up the discovery of new treatments for motor neurone disease (MND).

27 Mar 2012

ALS Association, AAN to honor KCL neurologist with Essey Award

The American Academy of Neurology and the ALS Association are awarding the 2012 Sheila Essey Award: An Award for ALS Research to Christopher Shaw, MBChB, MD, FRACP, with the Institute of Psychiatry at King's College London. Shaw will receive the award during the Academy's 64th Annual Meeting, April 21-28, 2012, in New Orleans.

22 Feb 2012